TAF1
protein-codingTATA-box binding protein associated factor 1, the group of Bromodomain containing|General transcription factor IID complex subunits |Lysine acetyltransferases
Gene summary
Initiation of transcription by RNA polymerase II requires the activities of more than 70 polypeptides. The protein that coordinates these activities is the basal transcription factor TFIID, which binds to the core promoter to position the polymerase properly, serves as the scaffold for assembly of the remainder of the transcription complex, and acts as a channel for regulatory signals. TFIID is composed of the TATA-binding protein (TBP) and a group of evolutionarily conserved proteins known as TBP-associated factors or TAFs. TAFs may participate in basal transcription, serve as coactivators, function in promoter recognition or modify general transcription factors (GTFs) to facilitate complex assembly and transcription initiation. This gene encodes the largest subunit of TFIID. This subunit binds to core promoter sequences encompassing the transcription start site. It also binds to activators and other transcriptional regulators, and these interactions affect the rate of transcription initiation. This subunit contains two independent protein kinase domains at the N- and C-terminals, but also possesses acetyltransferase activity and can act as a ubiquitin-activating/conjugating enzyme. Mutations in this gene result in Dystonia 3, torsion, X-linked, a dystonia-parkinsonism disorder. Alternative splicing of this gene results in multiple transcript variants. This gene is part of a complex transcription unit (TAF1/DYT3), wherein some transcript variants share exons with TAF1 as well as additional downstream DYT3 exons. [provided by RefSeq, Oct 2013]
- TAF2A
- BA2R
- CCG1
- CCGS
- DYT3
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~166.2 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: XL
Disease ID:MONDO:0010500
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: XL
Disease ID:MONDO:0010500
Submitter: Illumina
Inheritance Pattern: XL
Disease ID:MONDO:0010747
Submitter: Genomics England PanelApp
Inheritance Pattern: Unknown
Disease ID:MONDO:0010747
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: XL
Disease ID:MONDO:0010747
Submitter: Ambry Genetics
Inheritance Pattern: XL
Disease ID:MONDO:0010500
Submitter: Ambry Genetics
Inheritance Pattern: XL
Disease ID:MONDO:0010747
Submitter: Orphanet
Inheritance Pattern: XL
Disease ID:MONDO:0018823
Submitter: Orphanet
Inheritance Pattern: XL
Disease ID:MONDO:0010500
Submitter: PanelApp Australia
Inheritance Pattern: XL
Disease ID:MONDO:0010500
Submitter: G2P
Inheritance Pattern: XL
Disease ID:MONDO:0010747
Submitter: PanelApp Australia
Clinical Genomic Database (CGD)
Manifestation: Craniofacial; Musculoskeletal; Neurologic
Intervention: Neurologic
Rationale: Dystonia 3, torsion, X-linked may be responsive to levodopa
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to TAF1 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_004606.5. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 1 | 29 | 131 | 21 | 182 | |
| missense | 9 | 33 | 497 | 40 | 10 | 589 |
| nonsense | 22 | 22 | ||||
| start loss | 1 | 1 | 2 | |||
| frameshift | 1 | 3 | 4 | |||
| splice donor/acceptor (+/-2bp) | 1 | 56 | 57 | |||
| Total | 9 | 37 | 608 | 171 | 31 | 856 |
Highest pathogenic variant AF is 0.000001653312
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_004597.3 | 38 | MANE Select | |
| Ensembl | ENSP00000406549.2 | 38 | MANE Select | |
| RefSeq | NP_001273003.2 | 39 | Standard | |
| RefSeq | NP_001427781.1 | 39 | Standard |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| taf1 | Danio rerio | Structure: optic tectum Quality: decreased area abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Basal transcription factors - Homo sapiens (human)
- MECP2 and Associated Rett Syndrome
- Disease
- Gene expression (Transcription)
- hypoxia and p53 in the cardiovascular system
Biological Process
- protein polyubiquitination
- DNA-templated transcription, initiation
- regulation of transcription, DNA-templated
- transcription by RNA polymerase II
- transcription initiation from RNA polymerase II promoter
Molecular Function
- DNA-binding transcription factor activity, RNA polymerase II-specific
- p53 binding
- transcription coactivator activity
- histone acetyltransferase activity
- protein serine/threonine kinase activity
Cellular Component
- nuclear chromatin
- nucleus
- nucleoplasm
- transcription factor complex
- transcription factor TFIID complex
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000276072
- Coding exons
- 38
- Length
- 166111
- Individuals with no LoFs
- 125612
- Homozygous LoFs
- 3
- Heterozygous LoFs
- 14
- Defined
- 125629
- p
- 0.0000677
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 5.49 | 326 | 748 | 0.436 | 0.0000596 | 12563 |
| Missense (PolyPhen) | 82 | 312.02 | 0.2628 | 5365 | ||
| Synonymous | -1.07 | 272 | 250 | 1.09 | 0.0000182 | 3522 |
| Loss of Function | 7.69 | 0 | 68.9 | 0.00 | 0.00000538 | 1203 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0 | 0.0 | absent |
| Latino/Admixed American | 0 | 0.0 | absent |
| Ashkenazi Jewish | 0.00054 | 0.00040 | rare |
| East Asian | 0.00079 | 0.00060 | rare |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0.000012 | 0.0000088 | rare |
| South Asian | 0.000052 | 0.000033 | rare |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Largest component and core scaffold of the TFIID basal transcription factor complex (PubMed:25412659, PubMed:27007846). Contains novel N- and C-terminal Ser/Thr kinase domains which can autophosphorylate or transphosphorylate other transcription factors. Phosphorylates TP53 on 'Thr-55' which leads to MDM2- mediated degradation of TP53. Phosphorylates GTF2A1 and GTF2F1 on Ser residues. Possesses DNA-binding activity (PubMed:25412659). Essential for progression of the G1 phase of the cell cycle (PubMed:11278496, PubMed:15053879, PubMed:2038334, PubMed:8450888, PubMed:8625415, PubMed:9660973, PubMed:9858607). Exhibits histone acetyltransferase activity towards histones H3 and H4 (PubMed:15870300). {ECO:0000269|PubMed:11278496, ECO:0000269|PubMed:15053879, ECO:0000269|PubMed:15870300, ECO:0000269|PubMed:2038334, ECO:0000269|PubMed:25412659, ECO:0000269|PubMed:27007846, ECO:0000269|PubMed:8450888, ECO:0000269|PubMed:8625415, ECO:0000269|PubMed:9660973, ECO:0000269|PubMed:9858607}.;
- Disease
- DISEASE: Dystonia 3, torsion, X-linked (DYT3) [MIM:314250]: A X- linked dystonia-parkinsonism disorder. Dystonia is defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. DYT3 is characterized by severe progressive torsion dystonia followed by parkinsonism. It has a well-defined pathology of extensive neuronal loss and mosaic gliosis in the striatum (caudate nucleus and putamen) which appears to resemble that in Huntington disease. {ECO:0000269|PubMed:12928496, ECO:0000269|PubMed:17273961}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Mental retardation, X-linked, syndromic, 33 (MRXS33) [MIM:300966]: A mental retardation syndrome characterized by intellectual deficit, delayed psychomotor development, delayed speech and language, and characteristic facial features. Mental retardation is defined by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. {ECO:0000269|PubMed:26637982}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.180
Intolerance Scores
- LoFtool
- 0.152
- RVIS EVS
- -0.42
- RVIS percentile EVS
- 25.73
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- E
- Essential (gene trap)
- E
- Indispensability pred.
- E
- Indispensability score
- 1.00
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |